EUVIMEDScopri EUVIMED
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open access · CC BY-NC 4.0

A phase 1 evaluation of inhaled oxytocin: Physiologically‐based pharmacokinetic model informed dosing of a novel heat‐stable oxytocin delivery system

Pete Lambert, Carl M J Kirkpatrick iD, Rory Marriott, Siladitya Ray Chaudhuri, David Polidori, Bart Remmerie, Michelle P McIntosh

British Journal of Clinical Pharmacology · 2026-08 · 92 (8) · 2672-2681

DOI: 10.1002/bcp.70544 ↗

At a glance

Randomisierte kontrollierte Studie in British Journal of Clinical Pharmacology, published online on 2026-04-04. Written by Pete Lambert and 6 co-authors. Institution: Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. Major MEDLINE topics: Oxytocin, Models, Biological, Oxytocics, Drug Delivery Systems. 20 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Jansen Biotech, Inc, Victorian Medical Research Acceleration Fund.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Aim

To develop and validate a physiologically‐based pharmacokinetic (PBPK) model enabling inhaled oxytocin dose selection for clinical evaluation. Subsequently, to conduct a phase 1 study investigating the pharmacokinetics and safety of selected doses of an optimized inhaled oxytocin product in healthy, non‐pregnant female participants.

Method

A general PBPK model for inhaled oxytocin in non‐pregnant female participants was developed with the ability to estimate clinical exposure for new devices and deposition characteristics. This was used to select the oxytocin dose range for a randomized, single‐centre, partially single‐blind, placebo‐controlled, fixed‐sequence phase 1 study in comparison to standard of care injectable doses in a part cross‐over design. Participants received increasing inhaled oxytocin doses (150 μg, 300 μg, 600 μg and 900 μg) in single and/or repeat dose regimens. The primary endpoints were pharmacokinetic characteristics and local tolerability following inhaled dosing.

Results

Fifteen of 20 randomized participants completed the study. The pharmacokinetics following inhaled oxytocin administration were consistent with intramuscular dosing with the 150 μg (C max = 77 pg/mL, AUC 0‐inf = 2488 min.pg/mL) and 600 μg (C max = 398 pg/mL, AUC 0‐inf = 14 792 min.pg/mL) inhaled oxytocin doses bracketing the 10 IU intramuscular doses (C max = 197 pg/mL, AUC 0‐inf = 8560 min.pg/mL). Repeat dosing of inhaled oxytocin was well‐tolerated, and no significant treatment‐related adverse events or clinical findings were reported. The PBPK model accurately predicted key PK parameters within two‐fold of the observed values.

Conclusion

Further development of inhaled oxytocin as an innovative product to address preventable postpartum haemorrhage in low‐resource settings is warranted.

Trial registration

Australia New Zealand Clinical Trial Registry (ACTRN12622001077752p) registered 04/08/2022.

Subjects

MeSH terms (MEDLINE)

OxytocinModels, BiologicalOxytocicsDrug Delivery SystemsHumansFemaleCross-Over StudiesAdultSingle-Blind MethodAdministration, InhalationYoung AdultArea Under CurveDose-Response Relationship, Drug

Author keywords

inhaled deliverymaternal healthmaternal mortalitymodel‐informed developmentoxytocinphysiologically‐based pharmacokineticspostpartum haemorrhage

Substances

OxytocinOxytocics

Authors and institutions

  • Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
  • Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
  • Johnson & Johnson Innovative Medicine, USA.
  • Johnson & Johnson Clinical Pharmacology & Pharmacometrics, Belgium.

ORCID profiles: Carl M J Kirkpatrick

Funding

  • Jansen Biotech, Inc
  • Victorian Medical Research Acceleration Fund

Cite

APA

Lambert, P., Kirkpatrick, C. M. J., Marriott, R., Chaudhuri, S. R., Polidori, D., Remmerie, B., & McIntosh, M. P. (2026). A phase 1 evaluation of inhaled oxytocin: Physiologically‐based pharmacokinetic model informed dosing of a novel heat‐stable oxytocin delivery system. British Journal of Clinical Pharmacology, 92(8), 2672-2681. https://doi.org/10.1002/bcp.70544

Vancouver

Lambert P, Kirkpatrick CMJ, Marriott R, Chaudhuri SR, Polidori D, Remmerie B, et al. A phase 1 evaluation of inhaled oxytocin: Physiologically‐based pharmacokinetic model informed dosing of a novel heat‐stable oxytocin delivery system. British Journal of Clinical Pharmacology. 2026;92(8):2672-2681. doi:10.1002/bcp.70544

BibTeX
@article{Lambert2026,
  author = {Lambert, Pete and Kirkpatrick, Carl M J and Marriott, Rory and Chaudhuri, Siladitya Ray and Polidori, David and Remmerie, Bart and McIntosh, Michelle P},
  title = {A phase 1 evaluation of inhaled oxytocin: Physiologically‐based pharmacokinetic model informed dosing of a novel heat‐stable oxytocin delivery system},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  volume = {92},
  number = {8},
  pages = {2672--2681},
  doi = {10.1002/bcp.70544}
}
Start for free →